![Quiver Logo](/static/img/logo-icon.png)
![CYCCP logo](https://quiver-logos.s3.us-east-2.amazonaws.com/cyccp.png)
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view CYCCP Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of CYCCP by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by CYCCP's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to CYCCP
Recent picks made for CYCCP stock on CNBC
ETFs with the largest estimated holdings in CYCCP
Flights by private jets registered to CYCCP
![Quiver Logo](/static/img/logo-icon.png)